Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT05787834
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Best Practice — OTHER
    Receive usual care
  • Medical Device Usage and Evaluation — OTHER
    Wear accelerometer
  • Respiratory Muscle Training — PROCEDURE
    Undergo RMT
  • Survey Administration — OTHER
    Ancillary studies

Study Details

This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer. Over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. Aerobic exercise can help prevent the development of these side effects. However, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. Respiratory muscle training (RMT) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. Home-based RMT may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.

Key Dates

Start date
Oct 16, 2023
Status verified
May 2026
Primary completion
Oct 16, 2028
Completion
Oct 16, 2029

Study Design

Enrollment
130 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Active Comparator: Group I (low resistance RMT Group)
    Patients receive usual care for 12 weeks on study and a Respiratory Muscle training Device with small breathing resistance
  • Experimental: Group II (Moderate to highter resistance RMT)
    Patients undergo RMT using a respiratory muscle training device with moderate to higher breathing resistance for 12 weeks on study.

Primary Outcome Measure

Proportion of patients who participate in the study [ Time Frame: Up to 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263
Ellis Levine, MD
716-845-3152
Ellis Levine, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Buffalo, NY

Related Studies